DaltonTx Secures £4 Million Seed Funding to Develop Adaptive AI for Drug Discovery
DaltonTx, a UK-based technology company co-founded by Dr. Garry Pairaudeau, Adrian Rossall, Dr. Anthony Bradley, and Professor Charlotte Deane MBE, has emerged from stealth with £4 million in seed financing to develop adaptive artificial intelligence platforms for drug discovery. The round was backed by Redalpine, IQ Capital Partners, and Seedcamp, with support from Oxford University Innovation.
The founding team combines backgrounds in drug discovery, machine learning, and software engineering, with experience developing AI systems at AstraZeneca, Exscientia, and the University of Oxford.
The company is building an AI-enabled discovery system designed to integrate directly into pharmaceutical, biotech, and CRO workflows. DaltonTx describes its platform as a cloud-native AI system built to support the entire drug discovery process, from data ingestion and model training to molecule design and experiment prioritization.
It is designed to scale with research needs while remaining adaptable, learning continuously from scientists, models, and experiments to refine decisions over time. The company emphasizes “collaborative intelligence,” combining human expertise with machine learning to strengthen discovery outcomes, and positions the platform as suitable for both small molecules and biologics. The platform is intended to handle both small molecules and biologics, covering diverse therapeutic pipelines.
According to the investors, DaltonTx aims to position its technology as the “intelligence backbone” of R&D, offering adaptive infrastructure to speed timelines, reduce costs, and improve discovery outcomes across pharma and biotech organizations.
We track funding rounds like this weekly in Where Tech Meets Bio—our newsletter on startups, platforms, and deals at the intersection of biotech and digital.
Topic: Biotech Ventures
